HeartBeam Inc. (NASDAQ: BEAT), a medical-technology company developing advanced electrocardiogram solutions for remote cardiac care, has been recognized as a Global IP and Technology Leader in Portable Cardiac Diagnostics by PatentVest’s “Total Cardiac Intelligence” report (https://ibn.fm/ZuLCr). The company ranked second worldwide in 12-lead ECG innovation among 243 firms analyzed, trailing only GE Healthcare. This recognition highlights HeartBeam’s growing influence in the next generation of cardiac monitoring technology.
HeartBeam’s ranking underscores the rapid maturation of the company’s proprietary synthesis-ECG system, which captures the heart’s electrical signals in three noncoplanar dimensions and synthesizes them into a 12-lead ECG. This unique approach allows physicians to obtain comprehensive cardiac data remotely, potentially improving diagnosis and management of heart conditions. The company’s strong intellectual-property foundation is a major reason for its high placement in the report.
The HeartBeam System is a portable non-invasive recorder intended to record, store, and transfer a patient’s 3-Lead (in three directions) electrocardiogram acquired from 5 electrodes. The device is designed for use by adult patients in clinical settings or at home. It does not conduct cardiac analysis and can be used with an ECG Viewer software system for manual interpretation of non-life-threatening arrhythmias by a physician or healthcare professional.
This recognition from PatentVest positions HeartBeam as a key player in portable ECG technology, with implications for expanding access to cardiac monitoring outside traditional clinical settings. As remote healthcare continues to grow, innovations like HeartBeam’s synthesis-ECG system could play a crucial role in enabling timely cardiac assessments and reducing the burden on healthcare systems.
For more information on HeartBeam, visit the company’s newsroom at https://ibn.fm/BEAT.
